Beyond protection: Turning patent portfolios into commercial advantage

​
November 12, 2026

Why the strongest patent strategies begin with business value - not patent volume

The proposition

A patent portfolio can be legally impressive and commercially disappointing. The real test is not how many patents a business owns, but what those patents enable it to do. For many organisations, patents are still viewed primarily as defensive legal tools. But in today’s innovation-driven economy, the strongest portfolios do much more: they support growth, investment, partnerships, valuation and competitive advantage.

Patents remain important defensive rights. They can deter copying, create barriers to entry and provide leverage when a competitor gets too close. But protection is only the starting point. A portfolio creates real value when it is connected deliberately to the company’s products, markets, funding strategy and commercial relationships. Without that connection, even technically strong patents can become an expensive record of past innovation.

1. A patent is not valuable merely because it has been granted

A grant certificate proves that a legal threshold has been met. It does not prove that the patent protects a product customers want, covers a commercially important market or would survive a determined validity challenge.

That distinction matters because patents are expensive throughout their life. Filing, prosecution, overseas protection, translations, renewals and enforcement all compete for capital. The objective should not be to accumulate rights, but to build a portfolio whose scope, ownership and geographic coverage support a credible commercial position.

Nor is quantity a reliable proxy for strength. Five well-chosen patent families may do more for a business than fifty peripheral filings. Value depends on what the claims cover, how difficult they are to design around, whether the rights align with the market and whether the business can use them in practice.

The strongest portfolios are built with the end goal in mind from the beginning.

2. Start with the commercial objective

In my experience, the most productive patent discussions begin not with “Can we patent this?” but with “What commercial position are we trying to create?”

That question changes the conversation. It requires the business to identify the products and services that matter, the markets it expects to enter, the competitors or partners it may encounter and the capabilities that genuinely differentiate it. Filing decisions can then be tested against those objectives rather than driven by technical novelty alone.

This is critical in deep tech: quantum, artificial intelligence, life sciences, semiconductors and advanced engineering, where technologies and business models can evolve faster than the patent process. The portfolio must move with the business - not anchor it to an obsolete roadmap.

3. Use patents to create options: investment, licensing and partnerships

The commercial power of a patent is often its ability to create options. For an investor or acquirer, a coherent portfolio can evidence ownership, technical differentiation and a disciplined approach to future growth. It can support valuation, although it does not determine valuation on its own.

Patents can also make collaboration easier. Clearly defined rights help parties understand what each is bringing to a joint development, what access is required and how resulting technology may be commercialised. That clarity can reduce friction in negotiations with larger industrial partners, research institutions and other members of an innovation ecosystem.

Licensing adds another route to value. A business need not manufacture every product or enter every territory itself. Rights that are peripheral to one company’s strategy may be central to another’s. But licensing revenue is not automatic: it depends on market demand, useful claim scope, credible ownership and a counterparty with a commercial reason to take a licence.

4. Review ruthlessly: quality, relevance and cost

A portfolio should not be treated as a museum. Products change, markets close, competitors move and once-promising technologies lose relevance. Regular review is therefore as important as initial filing.

Each patent family should earn its place. Does it still support a current or credible future product? Is the protected market important? Does the right constrain a competitor, strengthen a negotiation or offer a realistic licensing opportunity? Are the likely benefits proportionate to the next round of prosecution and renewal costs?

Where the answer is no, sale, licensing or abandonment may be the disciplined choice. Pruning is not a sign that the original filing failed. It is evidence that the portfolio is being managed as a business asset.

5. Protection is only one part of the IP strategy

A balanced and credible strategy also recognises what patents cannot do. Patent ownership does not establish freedom to operate: a business may own valuable rights and still risk infringing an earlier third-party patent. Nor is patenting always the best answer. Filing requires disclosure, enforcement can be costly and some innovations are better protected through confidentiality, accumulated know-how, contractual controls, data advantages or speed to market.

The right question is therefore not whether patents are inherently valuable. It is where they add value relative to the alternatives. For some technologies, a patent will be the foundation of market exclusivity. For others, it will be one element in a broader package of rights and practical barriers that competitors cannot easily reproduce.

6. Conclusion: make the portfolio work for the business

The strongest patent strategies are neither filing exercises nor defensive reflexes. They are commercial disciplines. They connect protection decisions to products, markets, capital, partnerships and competitive choices - and they change when the business changes.

That means filing selectively, documenting ownership, reviewing the portfolio honestly and being clear about the outcome each right is intended to support. It also means recognising when another form of protection would serve the business better.

The goal is not simply to own patents. The goal is to make the portfolio work for the business.

Turn your patent portfolio into a commercial asset

Looking to get more value from your patents? Talk to our team about developing a patent strategy aligned with your commercial ambitions.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Beyond protection: Turning patent portfolios into commercial advantage
12 November 2026
A strong patent portfolio should do more than protect innovation. It should support the wider commercial ambitions of the business. This article explores how businesses can move beyond simply accumulating patents and instead build portfolios that create genuine commercial value. From aligning filing decisions with products and markets to supporting investment, licensing and partnerships, it considers how a focused patent strategy can strengthen competitive advantage while ensuring every right continues to earn its place.
#
Consulting
​
Samsung v ZTE: Will multiple rate setting trials become more common?
12 November 2026
The Samsung v ZTE dispute has highlighted the growing potential for multiple courts to determine FRAND rates within the same licensing dispute. This article explores how approaches in the UK, China and potentially the UPC could shape future FRAND litigation, the challenges posed by competing rate determinations, and whether arbitration could offer an alternative route to resolution.
#
Litigation
​
FRAND rate setting at the UPC: an emerging route for SEP owners?
10 November 2026
The UPC could be emerging as an important new forum for FRAND rate setting. Drawing on recent patentee-led actions and judicial commentary, this article explores how SEP owners might seek a UPC determination of FRAND terms and what this developing approach could mean for European enforcement and licensing strategies.
#
Litigation
​
Getting technical: Lessons from the emotional perception Remittal
28 October 2026
The Emotional Perception patent application has been refused again following its remittal to the UKIPO. The decision illustrates that clearing the relatively low threshold to qualify as an invention is only the first hurdle. For AI and other computer-implemented inventions, the crucial question is which features contribute to a technical solution to a technical problem and can therefore support inventive step.
#
Consulting
​
Quantum IP strategy: Own control points, not patent counts
14 October 2026
In quantum, the strongest portfolios will not be the biggest. Stuart Malcolm sets out six moves for owning the control points the market cannot route around, and the questions investors will ask.
#
Consulting
​
Targeted, not transformative: The UKIPO’s considered course on SEPs
13 October 2026
Andrew Sharples analyses the UKIPO's response to its SEP consultation, exploring proposed changes to FRAND dispute resolution, SEP transparency and licensing guidance, and what they mean for SEP holders and implementers.
#
Consulting
​
Chinese companies in European patent litigation
30 September 2026
Chinese companies are becoming increasingly active in European patent litigation, both as defendants and as patent owners enforcing their own rights. This article examines the growing role of Europe and the Unified Patent Court (UPC) in global patent disputes, highlighting key cases involving Chinese businesses and the strategic opportunities and risks that come with operating in European markets. It is the first in a series exploring the practical implications of European patent enforcement for Chinese companies.
#
Patenting
​
How to mitigate prior art traps for follow-on pharma patents
27 August 2026
Follow-on patents are increasingly important for pharmaceutical innovators. Learn how new EMA clinical trial disclosure rules create prior art risks and discover practical strategies to protect pharmaceutical IP and maximise patent value.
#
Consulting
​
Chinese companies and the UPC: from enforcement targets to strategic users
13 August 2026
Chinese companies are playing an increasingly significant role in UPC litigation, accounting for around 38% of infringement actions in 2025. While many remain defendants, a growing number are actively using the Unified Patent Court to enforce their own patent rights across Europe. The trend highlights the UPC's rising importance for Chinese businesses operating in sectors such as telecommunications, semiconductors, medical devices and renewable energy, and signals a shift in global patent enforcement strategy.
#
Patenting
​
Evaluating the environmental impact of patent AI.
31 July 2026
AI's environmental impact is rarely out of the headlines, but how does it compare to the benefits it delivers in practice? In this article, Laurence Brown examines the energy use of AI-assisted patent drafting, comparing it with traditional drafting workflows. While measuring AI's true environmental footprint is far from straightforward, the analysis suggests that AI-assisted patent drafting may already be more energy efficient, while delivering significant productivity gains for patent professionals.
#
Patenting
​
UPC appeals after three years: Early indications on appeal success rates
15 July 2026
Three years into the UPC, appeal overturn rates sit at 56% for both substantive and preliminary injunction cases, with Kodak v Fujifilm among the rulings reshaping outcomes on appeal.
#
Litigation
​
The UPC after three years: From experiment to enforcement forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
#
Litigation
​
Podcast: Building an AI-Native law firm
26 June 2026
On the Technically Legal podcast, EIP partner Laurence Brown discusses how Visser AI is redesigning patent workflows, letting the firm offer fixed fees without trading away speed or quality.
#
Patenting
​
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
#
Litigation
​
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
#
Consulting
​